Total mean (SD) | Propensity score matched (average treatment effects) coefficient (95% CI) | P value | Category % (n) normal (<10) | Category % (n) borderline (10-11) | Category % (n) positive (≥12) | NDBO versus P value | |

NDBO | 12.35 (4.51) | 30.5% (91) | 16.8% (50) | 52.7% (157) | |||

DBO | 12.67 (4.95) | −2.525 (−4.582 to −0.468) | 0.016* | 33.3% (16) | 16.7% (8 | 50.0% (24) | p=0.933 |

GORD | 10.88 (4.98) | 2.302 (0.984 to 3.621) | 0.001* | 45.7% (59) | 10.9% (14) | 43.4% (56) | p=0.01* |

Colonic polyp | 11.58 (3.93) | 0.717 (−0.441 to 1.875) | 0.225 | 36.2% (54) | 12.8% (19) | 51.0% (76) | p=0.355 |

Healthy | 10.02 (3.31) | 3.448 (1.969 to 4.927) | <0.001* | 47.9% (23) | 22.9% (11) | 29.2% (14) | p=0.007* |

This table compares all groups to the non-dysplastic cohort using both mean scores, after propensity score matching, and the categorical breakdown (normal, borderline and positive). P values are derived by Fisher’s exact test.

*p values <0.05 were deemed statistically significant.

DBO, dysplastic Barrett’s oesophagus; GORD, gastro-oesophageal reflux disease; NDBO, non-dysplastic Barrett’s oesophagus.